ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Survivors With Gene Variant At More Risk For Heart Disease

June 25, 2010

In The Courts: Lilly’s Claims Figured In Scripts Written To Coach Sales res, Court Documents Show

July 30, 1999

In brief: ring appointed Associate Dean At UCSF; Univ. of Utah Forms Cell Signaling Center

August 1, 1997

In Brief: visco Named to Cancer Policy Board; Foundation Pledges $6.5 Million to Karmanos

May 9, 1997

Report Outlines “Grand Challenges” For Chemistry

March 7, 2003

ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications

July 22, 2011